Autolus Therapeutics plc·4

Jul 1, 4:13 PM ET

Iannone Robert 4

Research Summary

AI-generated summary

Updated

Autolus (AUTL) Director Robert Iannone Receives Equity Awards

What Happened

  • Director Robert Iannone received two award grants on June 29, 2026 totaling 79,167 derivative equity awards (31,667 and 47,500 units). The reported acquisition price for both grants is $0.00, so no cash was paid at grant; the reported value at grant is $0 (derivative awards).
  • The filing (Form 4) was submitted on July 1, 2026 disclosing the June 29, 2026 awards.

Key Details

  • Transaction date: 2026-06-29; Form 4 filed: 2026-07-01 (timely filing indicated).
  • Awards: 31,667 and 47,500 derivative awards; total 79,167.
  • Price/Value: $0.00 per award as reported (derivative grant).
  • Vesting/terms (per footnotes):
    • Some awards are Restricted Stock Units (RSUs): each RSU is a contingent right to one American Depositary Share (ADS), and each ADS is convertible into one ordinary share (Footnote F1). RSUs vest in one installment on June 29, 2027 (F2).
    • Some awards are share options that vest in twelve equal monthly installments beginning July 29, 2026 (F3).
  • Shares owned after the transaction: not specified in the provided filing details.

Context

  • These are grant/award transactions (code A) — derivative awards that give the holder future exposure to company shares if vesting and other conditions are met. They are not open-market purchases or sales, and do not by themselves indicate the insider bought or sold shares.
  • RSUs convert to ADSs (and then to ordinary shares) upon vesting; options (if any in this grant package) will vest over 12 months per the footnote. Retail investors should note vesting timelines when assessing potential future dilution or insider incentives.